

China Generics Market Summary, Competitive Analysis and Forecast, 2017-2026

Industry Report | 2022-07-06 | 46 pages | MarketLine

AVAILABLE LICENSES:

- Single user licence (PDF) \$350.00
- Site License (PDF) \$525.00
- Enterprisewide license (PDF) \$700.00

Report description:

China Generics Market Summary, Competitive Analysis and Forecast, 2017-2026

Summary

Generics in China industry profile provides top-line qualitative and quantitative summary information including: market size (value 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Chinese generics market had total revenues of \$85.3bn in 2021, representing a compound annual growth rate (CAGR) of 7.3% between 2016 and 2021.
- Market consumption volume increased with a CAGR of 1.5% between 2016 and 2021, to reach a total of 97.0 % in 2021.
- Over the past five years, the Chinese market recorded growth of 7.8%. Growth in the market has been driven by demographic trends, primarily the general aging of the population.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in China
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in China

- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the China generics market with five year forecasts

Reasons to Buy

- What was the size of the China generics market by value in 2021?
- What will be the size of the China generics market in 2026?
- What factors are affecting the strength of competition in the China generics market?
- How has the market performed over the last five years?
- What are the main segments that make up China's generics market?

Table of Contents:

Table of Contents

- 1 Executive Summary
- 1.1. Market value
- 1.2. Market value forecast
- 1.3. Market volume
- 1.4. Market volume forecast
- 1.5. Geography segmentation
- 1.6. Market rivalry
- 1.7. Competitive Landscape
- 2 Market Overview
- 2.1. Market definition
- 2.2. Market analysis
- 3 Market Data
- 3.1. Market value
- 3.2. Market volume
- 4 Market Segmentation
- 4.1. Geography segmentation
- 5 Market Outlook
- 5.1. Market value forecast
- 5.2. Market volume forecast
- 6 Five Forces Analysis
- 6.1. Summary
- 6.2. Buyer power
- 6.3. Supplier power
- 6.4. New entrants
- 6.5. Threat of substitutes
- 6.6. Degree of rivalry
- 7 Competitive Landscape
- 7.1. Who are the leading players?
- 7.2. What are the strengths/weaknesses of the leading players?
- 7.3. Has there been any significant recent M&A activity?
- 7.4. How did the COVID-19 pandemic impact leading players?
- 8 Company Profiles
- 8.1. Teva Pharmaceutical Industries Limited

Scotts International, EU Vat number: PL 6772247784

- 8.2. Viatris Inc.
- 8.3. China Grand Pharmaceutical and Healthcare Holdings Limited
- 8.4. Pfizer Inc.
- 9 Macroeconomic Indicators
- 9.1. Country data
- 10 Appendix
- 10.1. Methodology
- 10.2. Industry associations
- 10.3. Related MarketLine research
- 10.4. About MarketLine



☐ - Print this form

To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

China Generics Market Summary, Competitive Analysis and Forecast, 2017-2026

Industry Report | 2022-07-06 | 46 pages | MarketLine

Select license	License				Price
	Single user licence (PDF)				\$350.00
	Site License (PDF)			\$525.00	
	Enterprisewide license (PDF)			\$700.00	
	VAT				
				Total	
** VAT will be added a	t 23% for Polish based comp	panies, individuals and EU based	companies who are	unable to provide a	valid EU
]** VAT will be added a	t 23% for Polish based comp	panies, individuals and EU based	companies who are	e unable to provide a	valid EU
	t 23% for Polish based comp		companies who are	e unable to provide a	valid EU
Email*	t 23% for Polish based comp	Phone*	companies who are	unable to provide a	valid EU
Email* [First Name* [t 23% for Polish based comp		companies who are	e unable to provide a	valid EU V
Email*	t 23% for Polish based comp	Phone*	companies who are	e unable to provide a	valid EU v
Email* [First Name* [t 23% for Polish based comp	Phone*		e unable to provide a	valid EU v
Email* [First Name* [ob title*	t 23% for Polish based comp	Phone* Last Name*		e unable to provide a	valid EU v
Email* [First Name* [ob title* [Company Name* [t 23% for Polish based comp	Phone* Last Name* EU Vat / Tax ID		e unable to provide a	valid EU v
Email* First Name* ob title* Company Name* [Address*	t 23% for Polish based comp	Phone* Last Name* EU Vat / Tax ID City*			valid EU v
Email* First Name* ob title* Company Name* [Address*	t 23% for Polish based comp	Phone* Last Name* EU Vat / Tax ID City* Country*	/ NIP number*		valid EU v

Scotts International. EU Vat number: PL 6772247784